Antiplatelet Therapy in ACS and A-Fib

Editor(s): Serebruany V.L. (Towson, Md.) 
Atar D. (Oslo) 
Table of Contents
Vol. 47, 2012
Section title: Paper

Antiplatelet Therapy in Acute Coronary Syndrome and Atrial Fibrillation: Aspirin

Tanguay J.-F.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Platelets play a critical role in the pathophysiology of acute coronary syndrome and thromboembolic complications associated with atrial fibrillation. Despite the development of newer and more potent antiplatelet agents, aspirin remains the cornerstone of antithrombotic therapy. Clinical trials conducted over the past decades have clearly established the safety and efficacy of aspirin therapy for the acute treatment and secondary prevention of acute myocardial infarction, ischemic stroke, and vascular death among patients at high risk for cardiovascular events. Although the absolute benefit of aspirin for primary prevention is lower than seen in secondary prevention trials, it is nevertheless an accepted preventive. This chapter provides a comprehensive overview of the clinical utility of aspirin in the setting of acute coronary syndrome and atrial fibrillation.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Roth GJ, Majerus PW: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624-632
  2. Burch JW, Stanford N, Majerus PW: Inhibition of platelet prostaglandin synthase by oral aspirin. J Clin Invest 1978;61:314-319
  3. Patrignani P, Filabozzi P, Patrono C: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372
  4. Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, Tack-Goldman K, Gay WAJr: Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-805
  5. López-Farré A, Caramelo C, Esteban A, Alberola ML, Millás I, Montón M, Casado S: Effects of aspirin on platelet-neutrophil interactions: role of nitric oxide and endothelin-1. Circulation 1995;91:2080-2088
  6. Bolz SS, Pohl U: Indomethacin enhances endothelial NO release: evidence for a role of PGI2 in the autocrine control of calcium-dependent autacoid production. Cardiovasc Res 1997;36:437-444
  7. Steer KA, Wallace TM, Bolton CH, Hartog M: Aspirin protects low density lipoprotein from oxidative modification. Heart 1997;77:333-337
  8. Patrono C, Collar B, Dalen J, Fuster V, Gent M, Harker L, Hirsh J, Roth G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998;114:470S-488S
  9. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Fillabozzi P, Catella F, Davi G, Forni L: Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:177-184
  10. Collaborative overview of randomized trials of antiplatelet therapy -I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308:81-106
  11. Antithrombotic Trialists’ CollaborationCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86
  12. Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, Harrington RA, Kong DF, Kandzari DE, Topol EJ: Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol 2004;43:972-978
  13. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990;336:827-830
  14. Wallentin LC: Research Group on Instability in Coronary Artery Disease in Southeast Sweden: Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 1991;18:1587-1593
  15. Nyman I, Larsson H, Wallentin L: Research Group on Instability in Coronary Artery Disease in Southeast Sweden: Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. Lancet 1992;340:497-501
  16. Juul-Möller S, AICardson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R: for the Swedish Angina Pectoris Aspirin Trial (SAPAT) GroupDoubleblind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-1425
  17. Graham DY: The relationship between nonsteroidal anti-inflammatory drug use and peptic ulcer disease. Gastroenterol Clin North Am 1990;19:171-182
  18. Gabriel SE, Jaakkimainen L, Bombardier C: Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A metaanalysis. Ann Intern Med 1991;115:787-796
  19. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ2nd: Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988;319:761-767
  20. Sandler DP, Burr FR, Weinberg CR: Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991;115:165-172
  21. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE: Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from metaanalysis of randomised trials. Heart 2001;85:265-271
  22. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL: Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313
  23. Wolff T, Miller T, Ko S: Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150:405-410
  24. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J: Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010;87:211-218
  25. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R: Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;926:313-316
  26. Final report on the aspirin component of the ongoing Physicians’ Health StudySteering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989;321:129-135
  27. ISIS-2 (Second International Study of Infarct Survival) Collaborative GroupRandomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360
  28. Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R, Faille D, Morange PE, Alessi MC, Bonnet JL: Aspirin noncompliance is the major cause of ‘aspirin resistance’ in patients undergoing coronary stenting. Am Heart J 2009;157:889-893
  29. Glauser J, Emerman CL, Bhatt DL, Peacock EF4th: Platelet aspirin resistance in ED patients with suspected acute coronary syndrome. Am J Emerg Med 2010;28:440-444
  30. Beigel R, Hod H, Fefer P, Asher E, Novikov I, Shenkman B, Savion N, Varon D, Matetzky S: Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol 2011;107:339-342
  31. Neubauer H, Kaiser AF, Endres HG, Kruger JC, Engelhardt A, Lask S, Pepinghege F, Kusber A, Mugge A: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance – the Bochum Clopidogrel and Aspirin Plan (BOCLA-Plan) to improve platelet therapy. BMC Med 2011;9:3
  32. Varon D, Spectre G: Antiplatelet agents. Hematology Am Soc Hematol Educ Program 2009;267-272
  33. Eikelboom JW, Hirsh J, Weitz JI, Johnson M, Yi Q, Yusuf S: Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655
  34. Cubbon RM, Abbas A, Wheatcroft SB, Kilcullen N, Das R, Morrell C, Barth JH, Kearney MT, Hall AS: for the EMMACE-2 Investigators: Diabetes mellitus and mortality after acute coronary syndrome as a first or recurrent cardiovascular event. PLoS One 2008;3:e3483
  35. Okada S, Morimoto T, Ogawa H, Kanauchi M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sakuma M, Saito Y: for the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes Trial Investigators: Differential effect of low-dose aspirin for the primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes Care 2011;34:1277-1283
  36. Roux S, Christeller S, Lüdin E: Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992;19:671-677
  37. Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983;309:396-403
  38. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuis P: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111
  39. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey BJ, Tanser PH: Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-1375
  40. Théroux P, Waters D, Qui S, McCans J, deGuis P, Juneau M: Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;881:2045-2048
  41. Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996;272:811-815
  42. Théroux P, Water D, Lam J, Luneau M, McCans J: Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145
  43. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R: A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974;1:436-440
  44. Aspirin in coronary heart diseaseThe Coronary Drug Project Research Group. J Chronic Dis 1976;29:625-642
  45. Elwood PC, Sweetnam PM: Aspirin and secondary mortality after myocardial infarction. Lancet 1979;2:1313-1315
  46. Persantine and aspirin in coronary heart diseaseThe Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980;62:449-461
  47. The Aspirin Myocardial Infarction Studyfinal results. The Aspirin Myocardial Infarction Study Research Group. Circulation 1980;62:(suppl V)V79-V84
  48. Breddin K, Loew D, Lechner K, Oberla K, Walter E: The German-Austrian Aspirin Trial: a comparison of acetylsalicylic acid, placebo, and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation 1980;62:(suppl V)V63-V72
  49. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-708
  50. Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, Ishikawa K, Masuda Y, Yamaguchi T, Motomiya T, Tamura Y: Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol 1999;83:1308-1313
  51. de Feyter PJ, van den Brand M, Laarman GJ, van Domburg R, Serruys PW, Suryapranata H: Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course management and follow-up. Circulation 1991;83:927-936
  52. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colonbo A, Goy JJ, van den Heuvel P, Delcan J, Morel M: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary disease. N Engl J Med 1994;331:489-495
  53. Betriu A, Masotti M, Serra A, Alonso J, Fernández-Avilés F, Gimeno F, Colman T, Zueco J, Delcan JL, García E, Calabuig J: Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 1999;34:1498-1506
  54. Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, Cleman MW, Cabin HS, Walker C, Stagg J, Buchbinder M, Teirstein PS, Topol EJ, Savage M, Perez JA, Curry RC, Whitworth H, Sousa JE, Tio F, Almagor Y, Ponder R, Penn IA, Leonard B, Levine SL, Fish D, Palmaz JC: Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991;83:148-161
  55. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulation therapy after the placement of coronaryartery stents. N Engl J Med 1996;334:1084-1089
  56. Heintzen MP, Heidland UE, Klimek WJ, Leschke M, Kelm M, Schwartzkopff B, Vester EG, Michel CJ, Strauer BE: Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial. Heart 2000;83:551-556
  57. Klimt CR, Knatterud GL, Stamler J, Meier P: Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986;7:251-269
  58. Schwartz L, Bourassa MG, Lespérance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719
  59. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671
  60. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Foz KA: for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) InvestigatorsEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533
  61. Steinhubl SR, Berger PB, Mann JT3rd, Fry ET, DeLago A, Wilmer C, Topol EJ: CREDO Investigators – Clopidogrel for the Reduction of Events during ObservationEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420
  62. Jolly SS, Poque J, Haladyn K, Peters RJ, Fox KA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR: Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 2009;30:900-907
  63. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S, et al: Starting aspirin therapy after operation: effects on early graft patency. Department of Veterans Affairs Cooperative Study Group. Circulation 1991;84:520-526
  64. Goldman S, Copeland J, Morwitz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, Lancaster L, Emery R, Sharma GVRK, Josa M, Pacold I, Montoya A, Parikh D, Sethi G, Holt J, Kirklin J, Shabetai R, Moores W, Aldridge J, Masud Z, DeMots H, Floten S, Haakenson C, Harker LA: Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988;77:1324-1332
  65. Gavaghan TP, Gebski V, Baron DW: Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery: a placebo-controlled, randomized study. Circulation 1991;83:1526-1533
  66. Goldman S, Copeland J, Morwitz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GVRK, Khuri S, Richards K, Grover F, Morrison D, Whitman G, Chesler E, Sako Y, Pacold I, Montoya A, DeMots H, Floten S, Doherty J, Read R, Scott S, Spooner T, Masud Z, Haakenson C, Kim T, Harker L: Long-term graft patency (3 years) after coronary artery surgery: effects of aspirin: results of a VA cooperative study. Circulation 1994;89:1138-1143
  67. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-368
  68. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-241
  69. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;351:1755-1762
  70. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD: for the Aspirin for Asymptomatic Atherosclerosis TrialistsAspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841-848
  71. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR: Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009;301:1909-1919
  72. Younis N, Williams S, Ammori B, Soran H: Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother 2010;11:1459-1466
  73. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J: Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010;87:211-218
  74. Simpson SH, Gamble JM, Mereu L, Chambers T: Effect of aspirin on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med 2011;26:1336-1344
  75. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS: Long-term aspirin use and mortality in women. Arch Intern Med 2007;167:562-572
  76. Berger JS, Brown DL, Burke GL, Oberman A, Kostis JB, Langer RD, Wong ND, Wassertheil-Smoller S: Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study. Circ Cardiovasc Qual Outcomes 2009;2:78-87
  77. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304
  78. Kjelsen SE, Kolloch RE, Leonetti G, Mallion JM, Zanchetti A, Elmfeldt D, Warnold I, Hansson L: Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens 2000;18:629-642
  79. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867
  80. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray Efor the BAFTA investigators and Midlan Research Practices Network (MidReC): Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503
  81. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes MIII, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM: Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2011. 2011 ACCF/ AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Updating the 2006 Guideline). Circulation 2011;123:104-123
  82. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-1912
  83. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S: Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00